Skip to main content
. 2013 Oct 9;2(1):87–92. doi: 10.3892/mco.2013.199

Figure 1.

Figure 1.

CT images of one partial response patient who experienced disease progression following a dose reduction of sorafenib. (A) Primary lesions prior to sorafenib treatment. (B) Primary lesion shrinkage after 4 months of sorafenib treatment; thereafter, sorafenib was reduced to 200 mg/day, mainly due to toxicity. (C) Primary lesions showing progression 4 months later.